Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Summary

The proposed Phase 1b study design was a randomized, placebo-controlled, double-blind, study to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.

Timeline

Start

2022-01-30

Primary completion

2022-04-30

Completion

2022-06-30

Outcome

Outcome not reported

Stopped: “The closure of the study is driven by the decision to redesign the study protocol for future studies.”

Drugs

Indications